This document is a translation of the original Japanese document for reference purposes only. In the event of any discrepancy between this document and the Japanese original, the original shall prevail.



August 13, 2025

Company name: MatsukiyoCocokara & Co.
Listing: Prime Market, Tokyo Stock Exchange

Stock code: 3088

Representative: Kiyoo Matsumoto,

President and Representative Director

Contact: Akio Ishibashi,

Managing Director,

Head of Group Management Planning

TEL: +81-3-6672-7808

Notice Concerning Acquisition of Shares of SHINSEIDOYAKKYOKU CO. LTD. by a Subsidiary of MatsukiyoCocokara & Co.

MatsukiyoCocokara & Co. hereby announces that at the Board of Directors meeting held on August 13, 2025, we resolved that our subsidiary, And Company Co.,Ltd. (hereinafter "And Company") will acquire shares of SHINSEIDOYAKKYOKU CO. LTD. (hereinafter "SHINSEIDOYAKKYOKU") and make it a subsidiary.

1. Reason for share acquisition

We based on our group vision "Making health and beauty more delightful and accessible", we actively incorporate new technologies and ideas mainly in the fields of health and beauty, aiming to make people's daily lives more fun and enjoyable. We continue to strive in its efforts to remain close and sensitive to the wishes and desires of consumers, and strive to deliver greater peace of mind and joy to the daily lives of people and their communities. In addition, we aim to expand our core business of Drugstore business and Dispensing Pharmacy business, as well as realize our vision of an alliance in which like-minded colleagues (companies) gather to achieve future growth together. To contribute to the creation of healthy communities, mainly in northern Kyushu, SHINSEIDOYAKKYOKU operates 119 dispensing pharmacies and drugstores as a group, and strives to extend healthy life expectancies and reduce social security costs. Since its establishment in 1978, SHINSEIDOYAKKYOKU has upheld the management philosophy of "helping people lead healthy lives," and aims to become the best healthcare station in the region by increasing the number of smiles on people's faces as much as possible.

In order to realize the alliance concept and further expand the scale of business, which were set as medium-term management targets for the fiscal year ending March 31, 2031, And Company has decided to acquire 100% of the shares of SHINSEIDOYAKKYOKU and invite it into the Group.

We believe that SHINSEIDOYAKKYOKU will continue to play an important role in expanding the Group's share in the northern Kyushu area and improving customer convenience by leveraging its strengths in dispensing pharmacies and drugstores with dispensing pharmacies, as well as the Group's know-how, resources, and various management resources.

In addition, And Company is a different group from both Matsumotokiyoshi Group and Cocokarafine Group. In order to demonstrate the uniqueness of each company as a trusted and supported family pharmacy and drugstore in each region, And Company will become an intermediate holding company newly established on August 1, 2025 as an organization that welcomes colleagues (companies) with a certain regional advantage to the Group.

$2.\ Overview\ of\ the\ transferred\ subsidiary\ (SHINSEIDOYAKKYOKU\ CO.\ LTD.)$

(1)	Company name	SHINSEIDOYAKKYOKU CO. LTD.	
(2)	Head office	3-12-17 Nakao, Minami-ku, Fukuoka-shi	
(3)	Title and name of	name of President Representative Director	
	the representative	Satoshi Mizuta	
(4)	Business description	Drugstore business, Dispensing pharmacy business	
(5)	Share capital 50 million yen		
(6)	Established	March 14, 1984	
(7)	Latest net sales	28,731 million yen (Fiscal year ended September 30, 2024, simple total with	
		subsidiaries)	
(8)	Major shareholders	Satoshi Mizuta (56.6%)	
	and percentage	Kaoru Mizuta (23.2%)	
	of shares	SHIP CO. LTD. (15.5%)	
(9)	Relationship with the	capital ties	No items to be reported
	company	human relationship	same as above
		business relationship	same as above

3. Overview of the counterparty to the share acquisition

(1)	Company Name	SHIP CO. LTD.	
(2)	Head office	3-12-17 Nakao, Minami-ku, Fukuoka-shi	
(3)	Title and name of the	Representative Director	
	representative person	Satoshi Mizuta	
(4)	Business description	Ownership, Managemen	t, Leasing, etc. of movable and real property
(5)	Share capital	1 million yen	
(6)	Established	September 3, 2012	
(7)	Relationship with the	Capital ties	No applicable items
	Company	Human relationship	same as above
		Business relationship	same as above
		Status of applicability	same as above
		for the party concerned	

4. Outline of the subsidiary acquiring the shares

	V 1 C		
(1)	Company Name	And Company Co.,Ltd.	
(2)	Head office	MK Ochanomizu Building, 7 f, 1-8-2 Yushima, Bunkyo-ku, Tokyo	
(3)	Title and name of the	Kiyoo Matsumoto, President of Representative Director	
	representative		
(4)	Business description	Management and supervision of Group companies such as Drugstores	
(5)	Share capital	50 million yen	
(6)	Established	August 1, 2025	
(7)	Major shareholders and	MatsukiyoCocokara & Co. (100.0%)	
	percentage of shares		

5. Number of shares to be acquired, acquisition price, and shareholding before and after the acquisition

(1)	Number of shares	0 shares	
	held before the	(Number of voting rights: 0)	
	transfer	(Percentage of voting rights: 0.0%)	
(2)	Number of shares	1,438 shares	
	bought back	(Number of voting rights: 1438)	
		(Percentage of voting rights: 100.0%)	
(3)	Cost	The acquisition price is determined in consultation with the counterparty based on	
		the results of the shareholder value calculation by a third party organization, but	
		we refrain from disclosing it due to the conclusion of a confidentiality agreement.	
(4)	Shares owned after	1,438 shares	
	the transaction	(Number of voting rights: 1438)	
		(Percentage of voting rights: 100.0%)	

6. Schedule

(1)	The date of	August 13, 2025
	resolution, Board of	
	Directors	
(2)	date of signing	August 13, 2025
	contract	
(3)	Date of share transfer	October 1, 2025 (scheduled)

7. Future Outlook

The impact of this matter on the Company's financial results for the fiscal year ending March 31, 2026 is currently under scrutiny, and the Company will promptly announce any matters that should be disclosed.

(Reference) Management Organizational Structure

